PTPRS and rheumatoid arthritis: This knowledge led to the demonstration that soluble versions of PTPRS Ig1&2 acting as a decoy markedly reduce the pathogenic activity of FLS in vitro and in vivo, providing implications for development of novel RA therapeutics to complement or synergize with existing ones (17, 21).